COVID-19 Treatment and Vaccine Tracker

Coronavirus cure: an exhaustive list of all the anti-viral drugs, antibody drugs and coronavirus vaccines in trial or racing to trial to defeat novel coronavirus

From the heystacks.com archiveUpdated 30 Apr 2024454 views

DiscussOpen original

View as text

NOTES:	Hidden		We need to think about streamlining these so that they're consistently headline or sentence capsed

0 Best Practices - Expand the formula bar so that you don't miss the additional info found in some of the cells. Reference the image to the right for more help. - Use filters to explore and organize the information for your own use. When accessing through this view-only link, filters are temporary to that search/find. - This document is also available for download under the File tab. - To find the latest additions or updates to the tracker, command+F or control+F and search for an asterisk. All cells with new information have an added at the end.							Last Update: May 21, 2020 \| 12:37 pm ET © 2020 Milken Institute00 2020

Number	Treatment vs. Vaccine	Product Category	Product Description	Stage of Development	Anticipated Next Steps	Clinical Trials for COVID-19	Developer / Researcher	Funder	Published Results	Clinical Trials for Other Diseases (T only) Related Use / Platform (V Only)	FDA-Approved Indications	Sources	Date Last Updated

1	Treatment	Antibodies	Polyclonal hyperimmune globulin (H-IG), unbranded	Pre-clinical	Phase 1 trials start in summer 2020. To patients between December 2020 and December 2021		CoVIg-19 Plasma Alliance (Takeda, CSL Behring, Biotest AG, Bio Products Laboratory, LFB, and Octapharma, ADMA Biologics, BioPharma Plasma, GC Pharma, Sanquin)/ National Institute of Allergy and Infectious Disease (NIAID)/ Microsoft (CoVIg-19 PlasmaBot)				N/A	Sources	5/10/2020	N/A	Sources

2	Treatment	Antibodies	Antibodies from mice, REGN3048-3051, against the spike protein	Pre-clinical	Start Phase 1 June 2020		Regeneron	Biomedical Advanced Research and Development Authority (BARDA)			N/A	Sources	Prior to 4/20/2020	N/A	Sources

3	Treatment	Antibodies	CT-P59; Antibodies from recovered COVID-19 patients	Pre-clinical	Start Phase 1 in July 2020		Celltrion	The Korea Health Industry Development Institute			N/A	Sources	5/14/2020	N/A	Sources

4	Treatment	Antibodies	Super-antibody or antibody cocktail to target potential mutations of SARS-CoV-2	Pre-clinical			Celltrion				N/A	Sources	Prior to 4/20/2020	N/A	Sources

5	Treatment	Antibodies	COVI-SHIELD antibody cocktail that binds to three different epitopes	Pre-clinical	Start Phase 2 trial 3Q 2020		Sorrento Therapeutics/ Mount Sinai Health System				N/A	Sources	5/20/2020	N/A	Sources

7	Treatment	Antibodies	Antibodies from recovered COVID-19 patients	Pre-clinical			Kamada/ Kedrion Biopharma				N/A	Sources	5/4/2020	N/A	Sources

8	Treatment	Antibodies	VIR-7831 and VIR-7832, antibodies from recovered SARS patients	Pre-clinical	Start Phase 2 ~ July-September 2020		Vir Biotechnology/GSK/ Samsung/WuXi Biologics/Biogen				N/A	Sources	5/20/2020	N/A	Sources

9	Treatment	Antibodies	Antibodies from recovered COVID-19 patients	Pre-clinical	Start Phase 1 in late July 2020		Eli Lilly/Ab-Cellera (NIH Vaccines Research Center)	Defense Advanced Research Projects Agency/ Government of Canada (ISED Strategic Innovation Fund)			N/A	Sources	5/5/2020	N/A	Sources

10	Treatment	Antibodies	COVID-19 Immunoglobulin, plasma derived	Pre-clinical			CSL Behring Australia				N/A	Sources	5/10/2020	N/A	Sources

Treatment	Antibodies	Avastin (bevacizumab), vascular endothelial growth factor inhibitor	Clinical	Phase 2/3 studies recruiting April 2020	NCT04275414 NCT04305106 NCT04344782	Numerous trials with Chinese research sponsors; Roche				FDA-approved since 2004, approved to treat certain types of cancer	Sources	4/27/2020	FDA-approved since 2004, approved to treat certain types of cancer	Sources	4/27/2020

11	Treatment	Antibodies	PD-1 blocking antibody; Thymosin	Clinical	Phase 2 study not yet recruiting	NCT04268537 ChiCTR2000030028	Numerous trials with Chinese research sponsors				Unknown	Sources	4/27/2020	Unknown	Sources

12	Treatment	Antibodies	Opdivo (nivolumab), PD-1 blocking antibody	Clinical	Phase 2 study not yet recruiting	NCT04356508 NCT04333914	University of Hong Kong (BMS)				FDA-approved since 2014, approved to treat melanoma and squamous non-small cell lung cancer	Sources	4/27/2020	FDA-approved since 2014, approved to treat melanoma and squamous non-small cell lung cancer	Sources

13	Treatment	Antibodies	leronlimab (PRO 140), a CCR5 antagonist	Clinical / Compassionate Use	Phase 2 trial started in April 2020; Phase 2b/3 trial starts April 2020	NCT04343651 NCT04347239	CytoDyn		CytoDyn	Treatment of HIV/AIDS, Graft versus Host Disease, Non-Alcoholic Steatohepatitis, and numerous cancers	N/A	Sources	Prior to 4/20/2020	N/A	Sources

14	Treatment	Antibodies	AiRuiKa (camrelizumab), anti-programmed cell death protein (PD-1) antibody	Clinical	No trial updates since February 2020	ChiCTR2000029806	Wuhan Jinyintan Hospital			Treatment of certain cancers	N/A	Sources	4/27/2020	N/A	Sources

15	Treatment	Antibodies	Kevzara (sarilumab), interleukin-6 receptor antagonist	Clinical	Started phase 2/3 in March 2020; preliminary Phase 2 results released April 27, 2020, trial continuing for only critical patients, Phase 3 (US) results expected June 2020, Phase 3 (ex-US) results expected 3Q 2020	NCT04315298 NCT04321993 NCT04341870 NCT04324073 NCT04327388 NCT04322773 NCT04345289 NCT02735707 NCT04357808 NCT04357860 NCT04359901	Sanofi/Regeneron; Feinstein Institutes; REMAP-CAP global trial	Biomedical Advanced Research and Development Authority (BARDA)	medRxiv (https://doi.org/10.1101/2020.04.23.20076612) Regeneron (https://newsroom.regeneron.com/index.php/news-releases/news-release-details/regeneron-and-sanofi-provide-update-us-phase-23-adaptive) ChinaXiv (http://www.chinaxiv.org/abs/202003.00026) medRxiv (https://doi.org/10.1101/2020.05.14.20094144)		FDA-approved since 2017, approved to treat rheumatoid arthritis	Sources	5/20/2020	FDA-approved since 2017, approved to treat rheumatoid arthritis	Sources

16	Treatment	Antibodies	Actemra (tocilizumab), interleukin-6 receptor antagonist	Clinical	Roche studies could be completed May or June 2020; Phase 2 open label study in Italy active (April 2020), Phase 3 studies recruiting April 2020, some results from open label study in France released April 2020	NCT04317092 NCT04320615 NCT04310228 ChiCTR2000030894 NCT04306705 ChiCTR2000030442 ChiCTR2000029765 NCT04322773 NCT04345445 NCT04331795 NCT04332094 NCT04346355 NCT04359667 NCT04332913 NCT04335071 NCT04356937 NCT04361032 NCT04315480 NCT04339712 NCT04333914 NCT04361552 NCT04330638 NCT04331808 NCT02735707 NCT04349410 NCT04363736 NCT04372186 NCT04363853	Numerous trials with global research sponsors; Roche; REMAP-CAP	Biomedical Advanced Research and Development Authority (BARDA)	ChinaXiv (http://www.chinaxiv.org/abs/202003.00026) medRxiv (https://doi.org/10.1101/2020.04.20.20061861) medRxiv (https://doi.org/10.1101/2020.04.23.20076612) Assistance Publique Hopitaux De Paris (https://www.aphp.fr/contenu/le-tocilizumab-ameliore-significativement-le-pronostic-des-patients-avec-pneumonie-covid) PNAS (https://www.pnas.org/content/early/2020/04/27/2005615117#T1) medRxiv (https://doi.org/10.1101/2020.05.01.20078360) medRxiv (https://doi.org/10.1101/2020.05.07.20094599) medRxiv (https://doi.org/10.1101/2020.05.14.20099234) medRxiv (https://doi.org/10.1101/2020.05.13.20100404) medRxiv (https://doi.org/10.1101/2020.05.13.20100081)		FDA-approved since 2010, approved to treat various type of arthritis, including rheumatoid arthritis, and cytokine release syndrome	Sources	5/21/2020	FDA-approved since 2010, approved to treat various type of arthritis, including rheumatoid arthritis, and cytokine release syndrome	Sources

17	Treatment	Antibodies	Gimsilumab, anti-granulocyte-macrophage colony stimulating factor monoclonal	Clinical	Phase 2 study started in April 2020	NCT04351243	Roivant Sciences				N/A	Sources	5/14/2020	N/A	Sources

18	Treatment	Antibodies	TJM2 (TJ003234), anti-granulocyte-macrophage colony stimulating factor antibody	Clinical	Phase 1/2 recruiting April 2020	NCT04341116	I-Mab Biopharma				N/A	Sources	4/27/2020	N/A	Sources

19	Treatment	Antibodies	lenzilumab, anti-granulocyte-macrophage colony stimulating factor antibody	Clinical / Compassionate Use	Phase 3 not yet recruiting April 2020	NCT04351152	Humanigen Inc.			Prevent cytokine storm with CAR-T cancer therapy; prevention/treatment of acute graft versus host disease; chronic myelomonocytic leukemia; eosinophilic asthma	N/A	Sources	4/27/2020	N/A	Sources

20	Treatment	Antibodies	Sylvant (siltuximab), interleukin-6 targeted monoclonal	Clinical / Compassionate Use	Compassionate use data shared April 2020; Phase 3 recruiting April 2020	NCT04322188 NCT04330638 NCT04329650	EUSA Pharma/The Papa Giovanni XXII Hospital; University Hospital, Ghent; Fundacion Clinic per a la Recerca Biomédica		EUSA Pharma (https://www.eusapharma.com/news/interim-analysis-data-for-siltuximab-treated-covid-19-patients-from-the-sisco-study/) medRxiv (https://doi.org/10.1101/2020.04.01.20048561) medRxiv (https://doi.org/10.1101/2020.04.23.20076612)		FDA-approved since 2014, approved to treat multicentric Castleman disease	Sources	4/28/2020	FDA-approved since 2014, approved to treat multicentric Castleman disease	Sources

21	Treatment	Antibodies	Soliris (eculizumab), complement inhibitor	Clinical/ Expanded access	Phase 2 recruiting May 2020	NCT04288713 NCT04346797 NCT04355494	Assistance Publique - Hopitaux de Paris (Phase 2); Alexion (Expanded Access)				FDA-approved since 2007, approved to treat Paroxysmal Nocturnal Hemoglobinuria, Atypical Hemolytic Uremic Syndrome, Generalized Myasthenia Gravis, and Neuromyelitis Optica Spectrum Disorder	Sources	5/5/2020	FDA-approved since 2007, approved to treat Par

coronavirus data healthcare coronavirus updates coronavirus vaccine coronavirus cure

Read source · Agent API · Licensing · Report content

Google SheetBreakdowns of COVID-19 (inc comparisons to ONS data on hisotircal respiratory disease) deathsThis is a collation of various data sets on UK COVID-19 deaths, as well as 5-year historical death totals and respiratory-related deaths. Primarily based on ONS data releases, but also combining various other sources of mortality figures for comparisons.
Google DocUnified research on privacy-preserving contact tracing and exposure notification for COVID-19This document has been created to share information across the numerous projects that are working to create mobile apps to help contact tracers fight COVID-19
Google DocFAQs on Protecting Yourself from Aerosol TransmissionThe goal of these FAQs is to provide information to the general public in an efficient manner about how to prevent aerosol transmission of COVID-19, with the hope that this will allow more informed decision making by individuals or organizations. It includes info about face masks and prevention of the infection. Face coverings (such as N95) can be useful for disease control alongside social distancing. Wearing face covering can help if you have coronavirus symptoms (such as coughs or sneezes) and is always better than no face mask. Other topics include: is coronavirus airborne, are covid masks safe, droplet precautions, airborne precautions, coronavirus masks, different types of close contact. These FAQs should always be similar or more stringent than information provided by Centers for Disease Control and Prevention (CDC), World Health Organization (WHO), and most regional & local health authorities.

Discussion 0

No discussion yet. Start it — no sign-up needed.

Related

Discussion 0